Avizorex Pharma, S.L.
http://
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Avizorex Pharma, S.L.
Aerie Misses Quick Path To Dry Eye Approval, But Is Still Moving Forward
AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- AVX Pharma
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice